Compare Novartis with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs FULFORD INDIA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS FULFORD INDIA NOVARTIS/
FULFORD INDIA
 
P/E (TTM) x 487.1 398.8 122.2% View Chart
P/BV x 28.3 6.2 454.6% View Chart
Dividend Yield % 1.6 0.1 1,911.0%  

Financials

 NOVARTIS   FULFORD INDIA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
FULFORD INDIA
Mar-14
NOVARTIS/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs758942 80.5%   
Low Rs579450 128.7%   
Sales per share (Unadj.) Rs228.4691.4 33.0%  
Earnings per share (Unadj.) Rs31.711.5 276.9%  
Cash flow per share (Unadj.) Rs32.815.4 213.3%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.3 520.6%  
Book value per share (Unadj.) Rs297.1380.0 78.2%  
Shares outstanding (eoy) m24.693.90 633.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.91.0 290.8%   
Avg P/E ratio x21.160.7 34.7%  
P/CF ratio (eoy) x20.445.3 45.0%  
Price / Book Value ratio x2.21.8 122.8%  
Dividend payout %31.517.4 180.6%   
Avg Mkt Cap Rs m16,5052,714 608.1%   
No. of employees `0000.70.4 150.5%   
Total wages/salary Rs m1,445505 286.2%   
Avg. sales/employee Rs Th8,441.36,073.0 139.0%   
Avg. wages/employee Rs Th2,163.61,137.4 190.2%   
Avg. net profit/employee Rs Th1,173.1100.7 1,165.2%   
INCOME DATA
Net Sales Rs m5,6392,696 209.1%  
Other income Rs m1,718125 1,370.3%   
Total revenues Rs m7,3572,822 260.7%   
Gross profit Rs m-63-46 134.7%  
Depreciation Rs m2515 166.4%   
Interest Rs m5510 582.1%   
Profit before tax Rs m1,57554 2,900.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m79210 8,245.8%   
Profit after tax Rs m78445 1,753.0%  
Gross profit margin %-1.1-1.7 64.4%  
Effective tax rate %50.317.7 284.2%   
Net profit margin %13.91.7 838.3%  
BALANCE SHEET DATA
Current assets Rs m9,5221,738 547.7%   
Current liabilities Rs m3,296545 605.1%   
Net working cap to sales %110.444.3 249.4%  
Current ratio x2.93.2 90.5%  
Inventory Days Days3748 75.5%  
Debtors Days Days284 660.3%  
Net fixed assets Rs m4612 386.6%   
Share capital Rs m12339 316.4%   
"Free" reserves Rs m7,2131,443 499.9%   
Net worth Rs m7,3361,482 495.0%   
Long term debt Rs m00-   
Total assets Rs m11,1052,077 534.8%  
Interest coverage x29.56.7 439.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.51.3 39.1%   
Return on assets %7.62.6 289.4%  
Return on equity %10.73.0 354.1%  
Return on capital %22.24.3 516.3%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m6117 352.3%   
Fx outflow Rs m3,630673 539.3%   
Net fx Rs m-3,570-656 544.2%   
CASH FLOW
From Operations Rs m1,61090 1,788.8%  
From Investments Rs m687105 656.8%  
From Financial Activity Rs m-2,677-14 18,982.3%  
Net Cashflow Rs m-380181 -210.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 2.0 3.8 52.6%  
FIIs % 1.6 0.1 1,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 21.2 101.4%  
Shareholders   41,647 4,783 870.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 13, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS